Progress risk assessment of oral premalignant lesions with saliva miRNA analysis

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yang, Ya ^a   Li, Yue xiu ^b   Yang, Xi ^a   Jiang, Long ^a   Zhou, Zuo jun ^a   Zhu, Ya qin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Tai'an Central Hospital   (China)

Author keywords

Malignant transformation; miRNAs; Oral leukoplakia; Risk assessment; Salivary biomarker

Indexed keywords

COMPLEMENTARY DNA; MICRORNA;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEUKOPLAKIA; MALE; MICROARRAY ANALYSIS; MOUTH SQUAMOUS CELL CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; RNA EXTRACTION; SALIVA LEVEL;

AGED; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; MICRORNAS; MIDDLE AGED; MOUTH NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; SALIVA; TUMOR MARKERS, BIOLOGICAL;

EID: 84875010699     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-129     Document Type: Article

References (23)

1. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008, 37(1):1-10.
2. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004, 54(3):150-180. 10.3322/canjclin.54.3.150, 15195789.
3. Wright JM. A review and update of oral precancerous lesions. Tex Dent J 1998, 115(6):15-19.
4. Bouquot JE, Weiland LH, Kirland LT. Leukoplakia and carcinoma in situ synchronously associated with invasive oral/oropharyngeal carcinoma in Rochester, Minn., 1935-1984. Oral Surg Oral Med Oral Pathol 1988, 65(2):199-207. 10.1016/0030-4220(88)90166-1, 3422724.
5. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci 2002, 99(24):15524-15529. 10.1073/pnas.242606799, 137750, 12434020.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838. 10.1038/nature03702, 15944708.
7. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043):839-843. 10.1038/nature03677, 15944709.
8. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005, 435(7043):828-833. 10.1038/nature03552, 15944707.
9. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA Translation and Stability by microRNAs. Annu Rev Biochem 2010, 79:351-379. 10.1146/annurev-biochem-060308-103103, 20533884.
10. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15(17):5473-5477. 10.1158/1078-0432.CCR-09-0736, 2752355, 19706812.
11. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: A new source of biomarkers. Mutat Res 2011, 717(1-2):85-90. 3199035, 21402084.
12. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biol 2010, 12(4):372-379. 10.1038/ncb2037, 2989719, 20190740.
13. Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnol 2010, 28(10):1057-1068.
14. Herceg Z, Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011, 727(3):55-61. 10.1016/j.mrrev.2011.04.001, 21514401.
15. Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Perez-Ordonez B, Gilbert R, Gullane P, Irish J, Kamel-Reid S. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 2009, 18(24):4818-4829. 10.1093/hmg/ddp446, 19776030.
16. Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, Villadsen SB, Bakholdt V, Bramsen JB, Sørensen JA, Krogdahl A, Clark SJ, Kjems J. MicroRNA Alterations and Associated Aberrant DNA Methylation Patterns across Multiple Sample Types in Oral Squamous Cell Carcinoma. PLoS One 2011, 6(11):e27840. 10.1371/journal.pone.0027840, 3222641, 22132151.
17. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. J oral path med 1996, 25(2):49-54.
18. von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G, Wendland K, Dienes HP, Engelmann U, Fries JW. MicroRNA 15a, inversely correlated to PKCα, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 2012, 180(5):1787-1797. 10.1016/j.ajpath.2012.01.014, 22429968.
19. Spielmann N, Wong DT. Saliva: diagnostics and therapeutic perspectives. Oral Dis 2011, 17(4):345-354. 10.1111/j.1601-0825.2010.01773.x, 3056919, 21122035.
20. Pekasky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006, 66(24):11590-11593. 10.1158/0008-5472.CAN-06-3613, 17178851.
21. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010, 39(4):493-506. 10.1016/j.molcel.2010.07.023, 2929389, 20797623.
22. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29(12):1787-1797. 10.1038/onc.2009.468, 2845743, 20023698.
23. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM. miR-181b is a biomarker of disease progressiong in chronic lymphocytic leukemia. Blood 2011, 118(11):3072-3079. 10.1182/blood-2011-01-333484, 3175784, 21636858.